19 Jan 2022 ‘Diagnosing Emerging Variants of SARS-CoV-2 for Effective Transmission Control’ article published in European Biopharmaceutical Review January 2022 delete this category
18 Jan 2022 Avacta Selects Second pre|CISIONTM Pro-drug Candidate for Development Investors | Therapeutics
10 Jan 2022 Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant Diagnostics | Investors
22 Dec 2021 AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing Diagnostics | Investors
15 Dec 2021 AffiDX® SARS-CoV-2 antigen lateral flow test detects the Omicron variant Diagnostics | Investors
29 Nov 2021 Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000 Investors | Therapeutics
16 Nov 2021 New Paper: Clinical evaluation of AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Blogs | Diagnostics
03 Nov 2021 Interview with Fiona McLaughlin – Avacta Chief Scientific Officer, Therapeutics Blogs | Therapeutics